Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (10): 933-938.DOI: 10.3969/j.issn.1673-8640.2024.10.002
Previous Articles Next Articles
MENG Qiang, WANG Shuang, BAI Zhou, HUANG Qian, FU Yang
Received:
2023-09-12
Revised:
2024-05-16
Online:
2024-10-30
Published:
2024-11-08
CLC Number:
MENG Qiang, WANG Shuang, BAI Zhou, HUANG Qian, FU Yang. Role of TLR9 of red blood cell membrane surface in sepsis patients with anemia[J]. Laboratory Medicine, 2024, 39(10): 933-938.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.10.002
组别 | 例数 | RBC计数/(×1012·L-1) | Hb/(g·L-1) | MCV/fL | MCH/pg |
---|---|---|---|---|---|
脓毒症组 | 237 | 3.23(2.64~3.79)***### | 96(79~113)***### | 96.5(91.5~101.7)***## | 30.4(28.8~31.5) |
普通感染组 | 241 | 3.61(2.90~4.18)*** | 106(88~128)*** | 95.0(91.2~98.6) | 30.4(29.2~31.6) |
正常对照组 | 206 | 4.78(4.48~5.06) | 145(134~155) | 94.2(92.3~96.3) | 30.4(29.7~31.2) |
组别 | MCHC/(g·L-1) | RDW-SD/fL | RDW-CV/% | RET%/% | |
脓毒症组 | 308(292~321)***### | 52.0(47.8~57.4)***### | 14.9(13.8~16.7)***# | 1.82(1.18~2.81)* | |
普通感染组 | 319(311~329)** | 50.1(45.8~56.0)*** | 14.6(13.4~16.6)*** | 1.85(1.33~2.75)*** | |
正常对照组 | 322(318-326) | 44.2(42.5~46.1) | 12.7(12.4~13.2) | 1.59(1.39~1.85) | |
组别 | RET#/(×109·L-1) | IRF/% | LFR/% | MFR/% | |
脓毒症组 | 57.6(36.1~90.4)***## | 14.4(9.50~23.00)*** | 85.6(77.0~90.5)*** | 11.4(8.2~14.6)*** | |
普通感染组 | 71.1(46.7~95.5)* | 13.4(8.45~20.25)*** | 86.6(79.8~91.6)*** | 10.8(7.2~13.8)*** | |
正常对照组 | 77.4(64.0~89.7) | 9.30(7.60~11.82) | 90.7(88.2~92.4) | 8.4(6.7~10.3) | |
组别 | HFR/% | RET-He/pg | RBC-O(×1012·L-1) | RBC-He/pg | |
脓毒症组 | 2.6(1.3~8.3)***# | 30.8(27.9~32.5)***# | 3.21(2.61~3.74)***### | 29.7(28.2~30.8)*** | |
普通感染组 | 2.1(1.0~6.5)*** | 31.7(28.6~33.7)*** | 3.53(2.83~4.14)*** | 29.7(28.4~31.0)*** | |
正常对照组 | 1.0(0.6~1.6) | 34.1(33.3~34.9) | 4.76(4.47~5.02) | 31.0(30.4~31.7) | |
组别 | RET-Y | RET-RBC-Y | IRF-Y | ||
脓毒症组 | 173.8(163.5~179.1)***# | 169.9(164.9~173.9)*** | 170.3(157.4~180.5)*** | ||
普通感染组 | 176.6(166.1~182.7)*** | 170.0(165.5~174.5)*** | 173.4(162.7~180.9)*** | ||
正常对照组 | 184.1(181.7~186.4) | 174.3(172.4~176.6) | 183.5(180.3~186.1) |
组别 | 例数 | RBC计数/(×1012·L-1) | Hb/(g·L-1) | MCV/fL | MCH/pg |
---|---|---|---|---|---|
脓毒症组 | 237 | 3.23(2.64~3.79)***### | 96(79~113)***### | 96.5(91.5~101.7)***## | 30.4(28.8~31.5) |
普通感染组 | 241 | 3.61(2.90~4.18)*** | 106(88~128)*** | 95.0(91.2~98.6) | 30.4(29.2~31.6) |
正常对照组 | 206 | 4.78(4.48~5.06) | 145(134~155) | 94.2(92.3~96.3) | 30.4(29.7~31.2) |
组别 | MCHC/(g·L-1) | RDW-SD/fL | RDW-CV/% | RET%/% | |
脓毒症组 | 308(292~321)***### | 52.0(47.8~57.4)***### | 14.9(13.8~16.7)***# | 1.82(1.18~2.81)* | |
普通感染组 | 319(311~329)** | 50.1(45.8~56.0)*** | 14.6(13.4~16.6)*** | 1.85(1.33~2.75)*** | |
正常对照组 | 322(318-326) | 44.2(42.5~46.1) | 12.7(12.4~13.2) | 1.59(1.39~1.85) | |
组别 | RET#/(×109·L-1) | IRF/% | LFR/% | MFR/% | |
脓毒症组 | 57.6(36.1~90.4)***## | 14.4(9.50~23.00)*** | 85.6(77.0~90.5)*** | 11.4(8.2~14.6)*** | |
普通感染组 | 71.1(46.7~95.5)* | 13.4(8.45~20.25)*** | 86.6(79.8~91.6)*** | 10.8(7.2~13.8)*** | |
正常对照组 | 77.4(64.0~89.7) | 9.30(7.60~11.82) | 90.7(88.2~92.4) | 8.4(6.7~10.3) | |
组别 | HFR/% | RET-He/pg | RBC-O(×1012·L-1) | RBC-He/pg | |
脓毒症组 | 2.6(1.3~8.3)***# | 30.8(27.9~32.5)***# | 3.21(2.61~3.74)***### | 29.7(28.2~30.8)*** | |
普通感染组 | 2.1(1.0~6.5)*** | 31.7(28.6~33.7)*** | 3.53(2.83~4.14)*** | 29.7(28.4~31.0)*** | |
正常对照组 | 1.0(0.6~1.6) | 34.1(33.3~34.9) | 4.76(4.47~5.02) | 31.0(30.4~31.7) | |
组别 | RET-Y | RET-RBC-Y | IRF-Y | ||
脓毒症组 | 173.8(163.5~179.1)***# | 169.9(164.9~173.9)*** | 170.3(157.4~180.5)*** | ||
普通感染组 | 176.6(166.1~182.7)*** | 170.0(165.5~174.5)*** | 173.4(162.7~180.9)*** | ||
正常对照组 | 184.1(181.7~186.4) | 174.3(172.4~176.6) | 183.5(180.3~186.1) |
项目 | 二项式拟合公式 | r值 | P值 |
---|---|---|---|
RBC计数 | Y=4.750-0.143X-0.003X2 | -0.418 | <0.001 |
Hb | Y=152.3-6.039X+0.144X2 | -0.470 | <0.001 |
RET# | Y=81.96-1.696X-0.050X2 | -0.398 | <0.001 |
RBC-O | Y=4.979-0.175X+0.004X2 | -0.464 | <0.001 |
MCHC | Y=335.4-2.878X+0.093X2 | -0.260 | <0.01 |
RET-He | Y=33.94-0.389X-0.000 5X2 | -0.352 | <0.001 |
RET-Y | Y=183.4-1.263X-0.009X2 | -0.352 | <0.001 |
RDW-SD | Y=41.24+1.325X+0.037X2 | 0.399 | <0.001 |
RDW-CV | Y=12.61+0.316X-0.007X2 | 0.440 | <0.001 |
项目 | 二项式拟合公式 | r值 | P值 |
---|---|---|---|
RBC计数 | Y=4.750-0.143X-0.003X2 | -0.418 | <0.001 |
Hb | Y=152.3-6.039X+0.144X2 | -0.470 | <0.001 |
RET# | Y=81.96-1.696X-0.050X2 | -0.398 | <0.001 |
RBC-O | Y=4.979-0.175X+0.004X2 | -0.464 | <0.001 |
MCHC | Y=335.4-2.878X+0.093X2 | -0.260 | <0.01 |
RET-He | Y=33.94-0.389X-0.000 5X2 | -0.352 | <0.001 |
RET-Y | Y=183.4-1.263X-0.009X2 | -0.352 | <0.001 |
RDW-SD | Y=41.24+1.325X+0.037X2 | 0.399 | <0.001 |
RDW-CV | Y=12.61+0.316X-0.007X2 | 0.440 | <0.001 |
[1] | LIANG Y W, ZHU Y F, ZHANG R, et al. Incidence,prognosis,and risk factors of sepsis-induced cardiomyopathy[J]. World J Clin Cases, 2021, 9(31):9452-9468. |
[2] |
LOFTUS T J, MIRA J C, STORTZ J A, et al. Persistent inflammation and anemia among critically ill septic patients[J]. J Trauma Acute Care Surg, 2019, 86(2):260-267.
DOI PMID |
[3] | BISHT K, TAY J, WELLBURN R N, et al. Bacterial lipopolysaccharides suppress erythroblastic islands and erythropoiesis in the bone marrow in an extrinsic and G- CSF-,IL-1-,and TNF-independent manner[J]. Front Immunol, 2020, 11:583550. |
[4] | KOU M, WANG L. Surface toll-like receptor 9 on immune cells and its immunomodulatory effect[J]. Front Immunol, 2023, 14:1259989. |
[5] | LAM L K M, MURPHY S, KOKKINAKI D, et al. DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia[J]. Sci Transl Med, 2021, 13(616):eabj1008. |
[6] |
JO Y H, KIM K, LEE J H, et al. Red cell distribution width is a prognostic factor in severe sepsis and septic shock[J]. Am J Emerg Med, 2013, 31(3):545-548.
DOI PMID |
[7] | OLINDER J, EHINGER D, LILJENBORG E, et al. Plasma levels of hepcidin and reticulocyte haemoglobin during septic shock[J]. J Innate Immun, 2020, 12(6):448-460. |
[8] | SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. JAMA, 2016, 315(8):801-810. |
[9] | 中国医疗保健国际交流促进会急诊医学分会, 中华医学会急诊医学分会, 中国医师协会急诊医师分会, 等. 中国“脓毒症早期预防与阻断”急诊专家共识[J]. 中华危重病急救医学, 2020, 32(5):518-530. |
[10] | 安萌萌, 龚平. 脓毒症相关性贫血发病机制及治疗的研究进展[J]. 中华急诊医学杂志, 2018, 27(10):1175-1178. |
[11] |
CORWIN H L, SURGENOR S D, GETTINGER A. Transfusion practice in the critically ill[J]. Crit Care Med, 2003, 31(12 Suppl):S668-S671.
DOI PMID |
[12] | WEIMANN A, CREMER M, HERNÁIZ-DRIEVER P, et al. Delta-He,Ret-He and a new diagnostic plot for differential diagnosis and therapy monitoring of patients suffering from various disease-specific types of anemia[J]. Clin Lab, 2016, 62(4):667-677. |
[13] |
BUORO S, MANENTI B, SEGHEZZI M, et al. Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit[J]. J Clin Pathol, 2018, 71(4):330-335.
DOI PMID |
[14] | WANG A Y, MA H P, KAO W F, et al. Red blood cell distribution width is associated with mortality in elderly patients with sepsis[J]. Am J Emerg Med, 2018, 36(6):949-953. |
[15] | DINKLA S, VAN EIJK L T, FUCHS B, et al. Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane[J]. BBA Clin, 2016, 5:186-192. |
[16] | CHAN C Y, CHENG C F, SHUI H A, et al. Erythrocyte degradation,metabolism,secretion,and communication with immune cells in the blood during sepsis:a review[J]. Tzu Chi Med J, 2021, 34(2):125-133. |
[17] | SABER M M, MONIR N, AWAD A S, et al. TLR9:a friend or a foe[J]. Life Sci, 2022, 307:120874. |
[18] | HOTZ M J, QING D, SHASHATY M G S, et al. Red blood cells homeostatically bind mitochondrial DNA through TLR9 to maintain quiescence and to prevent lung injury[J]. Am J Respir Crit Care Med, 2018, 197(4):470-480. |
[1] | WANG Tiankai, LIU Lin, JIN Peipei, WANG Fang, DING Ning. Clinical value of new neutrophil parameter NEU-X,NEU-Y and NEU-Z in diagnosis of sepsis [J]. Laboratory Medicine, 2024, 39(7): 682-686. |
[2] | LIU Xiaowen, SHAO Wenqi, ZHU Jing, YANG Jing, ZHANG Chunyan, PAN Baishen, WANG Beili, GUO Wei. Establishment of reference interval of serum ferritin in adults in Shanghai by indirect method [J]. Laboratory Medicine, 2024, 39(6): 524-529. |
[3] | JIANG Jingjing, GU Ping, WANG Chengyun, ZHANG Fan, SHEN Huiying, PAN Qiuhui, WANG Jing. Changes and clinical significance of procalcitonin and coagulation function indicators in children with sepsis [J]. Laboratory Medicine, 2024, 39(6): 573-577. |
[4] | LIANG Dong, MEI Yue, WANG Tengjiao, YU Dong. Characteristic of blood microbiota of postoperative sepsis based on cfDNA NGS [J]. Laboratory Medicine, 2023, 38(8): 753-759. |
[5] | ZHAO Xiaomin, JIANG Xiaoyu, SHAN Kaili, SHAN Tieying, LIU Xiuzhen. Roles of Flt-3L,TF and 25(OH)D in iron deficiency anemia among infants and children [J]. Laboratory Medicine, 2022, 37(11): 1039-1043. |
[6] | PAN Xilong, XU Zhiyuan, XIE Feng, LI Dan. Role of procalcitonin in the diagnosis of different sepsis [J]. Laboratory Medicine, 2021, 36(12): 1215-1218. |
[7] | HU Senan, AI Honghong, YE Xuelian, CHENG Jiangyan. Relationship between complement 3,interleukin 35 and the severity and prognosis of sepsis [J]. Laboratory Medicine, 2021, 36(1): 25-29. |
[8] | FU Jing, TU Xing. Serum high mobility group box-1 expression in patients with sepsis caused by bacteria and its clinical significant [J]. Laboratory Medicine, 2021, 36(1): 80-83. |
[9] | ZHANG Hongxia, HAN Hong. Changes and roles of sST2,SF and hepcidin levels in patients with CHF and anemia [J]. Laboratory Medicine, 2020, 35(9): 912-916. |
[10] | LU Jiacai, HUANG Ying, MO Yang, ZHOU Xiaofen, YAO Xin. Role of CD55,CD59 and FLAER combined determination for the diagnosis of PNH [J]. Laboratory Medicine, 2020, 35(6): 566-569. |
[11] | TANG Lin, ZHANG Xiaojing, TANG Zhenhua. Investigation of gestational anemia in Shanghai,2016 [J]. Laboratory Medicine, 2020, 35(2): 116-119. |
[12] | CHEN Shiyang, FU Xiaoying, XU Gang, LIN Zhenhu, LUO Meizhu, MAI Huirong, CHEN Yunsheng, LIU Sixi. Monitoring lymphocyte subsets after β-mediterranean anemia allogeneic hematopoetic stem cell transplantation in children [J]. Laboratory Medicine, 2019, 34(12): 1066-1071. |
[13] | YAN Kuanghua, ZHANG Tiansheng. Role of serum carbohydrate antigen 153 determination in the disease course of megaloblastic anemia [J]. Laboratory Medicine, 2019, 34(12): 1111-1113. |
[14] | ZHOU Chunlei, CHEN Ruping, WANG Kai, GAO Qiang, MU Hong. Role of serum soluble transferrin receptor in the diagnosis of adult iron deficiency anemia [J]. Laboratory Medicine, 2019, 34(11): 1002-1006. |
[15] | CHEN Xiaoyan. Serum procalcitonin level for guiding the discontinuation of antibiotics in patients with urinary sepsis [J]. Laboratory Medicine, 2018, 33(9): 794-797. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||